Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2002-08-12
2008-10-07
Richter, Johann (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S002600, C514S018700, C514S019300, C514S740000
Reexamination Certificate
active
07432301
ABSTRACT:
The present invention is directed to a method of treating disordered control of breathing including the treatment of apnea and hypoventilation associated with congenital or acquired brain stem abnormalities. Specifically the invention is directed to treating disordered control of breathing by administering an S-nitrosylating agent selected from the group consisting of ethyl nitrite, glutathione, nitric oxide, S-nitrosocysteine, S-nitrosoglutathione, S-nitro-N-acetyl cysteine. As shown in FIG.1C the ability of endogenous SNOgto increase VEin freely behaving, conscious rates using whole-body plethysmography revealed that CSNO, GSNO and CGSNO (1 nmol each) caused equivalent increases in VE, whereas D-CSNO had no effect (left bar graph is the equivalent increases in VE, whereas D-CSNO had no effect (left bar graph is the control whereas the right bar represents administration of the respective SNO).
REFERENCES:
patent: 4900719 (1990-02-01), Means et al.
patent: 5380758 (1995-01-01), Stamler et al.
patent: 5508045 (1996-04-01), Harrison et al.
patent: 5570683 (1996-11-01), Zapol et al.
patent: 5574068 (1996-11-01), Stamler et al.
patent: 5593876 (1997-01-01), Stamler et al.
patent: 5612314 (1997-03-01), Stamler et al.
patent: 6314956 (2001-11-01), Stamler et al.
patent: 6331543 (2001-12-01), Garvey et al.
patent: 6352975 (2002-03-01), Schreiner et al.
patent: 6586478 (2003-07-01), Ackman et al.
patent: 6974814 (2005-12-01), Radulovacki et al.
patent: 2002/0002136 (2002-01-01), Herbert
patent: 2002/0106404 (2002-08-01), Lipton
patent: WO 92/17455 (1992-10-01), None
Gaston et al., “Stereoselective increase in minute ventilation caused by S-nitroso-L-cysteine administration to the nucleus tractus solitarius of the rat: An hypoxic signalling mechanism?”; Sep. 1999, Acta Physiologica Scandinavica, vol. 167, No. Suppl. 645.
Weiskopf, R. “Use of Inhaled Nitric Oxide Perioperatively and in Intensive Care Patients”, Anesthesiology, 2000, 92(6), pp. 1821-1825.
Funayama, T., Sekizawa, K., Yamaya, M., Yamauchi, K., Ohno, I., Ohrui, T., Terajima, M., Okinaga, S. and Sasaki, H. (1996). “Role of Leukotriene-degrading Enzymes in Pulmonary Response to Antigen Infusion in Sensitized Guinea Pigs In Vivo.” Am. J . Respir. Cell Mol. Biol., vol. 15, pp. 260-267.
Hogg, N., Singh, R. J., Joseph, J. and Kalyanaraman, B. (1997). “S-Nitrosoglutathione as a substrate for gamma-glutamyl transpeptidase.” Biochem. J., vol. 323, pp. 477-481.
The Merck Index, 12th edition, items 911 and 917 (1996).
The Merck Index, 11th edition, pp. 14 and 436 (1989).
Gaston, B., Sears, S., Woods, J., Hunt, J., Ponaman, M., McMahon, T. and Stamler, J. S. (1998). “Bronchodilator S-nitrosothiol deficiency in asthmatic respiratory failure.” The Lancet. vol. 351,No. 9112, pp. 1317-1319.
Minamiyama, Y., Takemura, S., Koyama, K., Yu, H., Miyamoto, M. and Inoue, M. (1996). “Dynamic aspects of glutathione and nitric oxide metabolism in endotoxemic rats.” Am. J. Physiol. vol. 271 (Gastrointest. Liver Physiol. 34): G575-G581.
Aldrich Chemical Company Catalog (1992) p. 15, item 3806-1.
Sigma Catalog (1991) item A7250.
Singh, S. P., Wishnok, J. S., Keshive, M., Deen, W. M. and Tannebaum, S. R. (1996). “The chemistry of the S-nitrosoglutathione/glutathione system.” Pro. Natl. Acad. Sci. USA, vol. 93, pp. 14428-14433.
Singh, R., Hogg, N., Joseph, J. and Kalyanaraman, B. (1996). “Mechanism of Nitric Oxide Release from S-Nitrosothiols.” The Journal of Biological Chemistry, vol. 271, No. 31, pp. 18596-18603.
Gaston, B., Reilly, J., Drazen, J. M., Fackler, J., Ramdev, P., Arnelle, D., Mullins, M. E., Sugarbaker, D.J., Chee, C., Singel, D. J., Loscalzo, J. and Stamler, J. S. (1993). “Endogenous nitrogen oxides and bronchodilator S-nitrosothiols in human airways.” Proc. Natl. Acad. Sci. USA, vol. 90, pp. 10957-10961.
Stamler, J. S. and Toone, E. J. (2002). “The decomposition of thionitrites.” Current Opinion in Chemical Biology, vol. 6, pp. 779-785.
Snyder, D. W., Aharony, D., Dobson, P., Tsai, B. S. and Krell, R. D. (1984). “Pharmacological and Biochemical Evidence for Metabolism Peptide Leukotrienes by Guinea-Pig Airway Smooth Muscle In Vitro.” Journal of Pharmacology and Experimental Therapeutics, vol. 231, pp. 224-229.
Nabe, T., Kohno, S., Tanpo, T., Saeki, Y., Yamaura, H., Moriba, M. and Obata, K. (1994). “Inhibitory effect on ONO-1078 on specific binding of peptide leukotrienes to human lung crude membrane.” Prostaglandins Leukotrienes & Essential Fatty Acids. vol. 51, No. 3, pp. 163-171.
Gaston, B., Sears, S., Wlton, S., Woods, J., Hunt, J., Arnelle, D. and Stamler, J. S., Mini-Sympsium, p. A945, item D75.
Gaston Benjamin M.
Gozal David
Acevedo James H Alstrum
Richter Johann
Sparks Rodney L.
University of Louisville Research Foundation
University of Virginia Patent Foundation
LandOfFree
Use of S-nitrosothiol signaling to treat disordered control... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of S-nitrosothiol signaling to treat disordered control..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of S-nitrosothiol signaling to treat disordered control... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3988517